Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.

Portella Costa, T; Bordin, DM; Nóbrega Aoki, M; Blanes, L

Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.

Portella Costa, T Bordin, DM Nóbrega Aoki, M Blanes, L

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Virol J, 2025, 22, (1), pp. 206
Issue Date:: 2025-06-24

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.04 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Portella Costa, T
dc.contributor.author	Bordin, DM
dc.contributor.author	Nóbrega Aoki, M
dc.contributor.author	Blanes, L
dc.date.accessioned	2025-08-18T22:11:43Z
dc.date.available	2025-05-07
dc.date.available	2025-08-18T22:11:43Z
dc.date.issued	2025-06-24
dc.identifier.citation	Virol J, 2025, 22, (1), pp. 206
dc.identifier.issn	1743-422X
dc.identifier.issn	1743-422X
dc.identifier.uri	http://hdl.handle.net/10453/189456
dc.description.abstract	PURPOSE: Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil. METHODS: This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements. RESULTS: Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects. CONCLUSIONS: Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP's mechanisms of action and its integration into broader therapeutic strategies.
dc.format	Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	Virol J
dc.relation.isbasedon	10.1186/s12985-025-02778-8
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0605 Microbiology, 1108 Medical Microbiology
dc.subject.classification	Virology
dc.subject.classification	3107 Microbiology
dc.subject.mesh	Humans
dc.subject.mesh	COVID-19
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	COVID-19 Serotherapy
dc.subject.mesh	Aged
dc.subject.mesh	Brazil
dc.subject.mesh	Adult
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	C-Reactive Protein
dc.subject.mesh	Survival Rate
dc.subject.mesh	Kaplan-Meier Estimate
dc.subject.mesh	Humans
dc.subject.mesh	C-Reactive Protein
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	Survival Rate
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Brazil
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Kaplan-Meier Estimate
dc.subject.mesh	COVID-19
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	COVID-19 Serotherapy
dc.subject.mesh	Humans
dc.subject.mesh	COVID-19
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Immunization, Passive
dc.subject.mesh	COVID-19 Serotherapy
dc.subject.mesh	Aged
dc.subject.mesh	Brazil
dc.subject.mesh	Adult
dc.subject.mesh	SARS-CoV-2
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Antibodies, Viral
dc.subject.mesh	C-Reactive Protein
dc.subject.mesh	Survival Rate
dc.subject.mesh	Kaplan-Meier Estimate
dc.title	Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.
dc.type	Journal Article
utslib.citation.volume	22
utslib.location.activity	England
utslib.for	0605 Microbiology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2025-08-18T22:11:41Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	22
utslib.citation.issue	1

Abstract:

PURPOSE: Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil. METHODS: This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements. RESULTS: Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects. CONCLUSIONS: Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP's mechanisms of action and its integration into broader therapeutic strategies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/189456